Navigation Links
Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
Date:10/19/2009

EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) ("NTI") announced today it has submitted written notice to the NASDAQ Stock Market LLC ("NASDAQ") that NTI intends to file a Form 25 with the Securities and Exchange Commission ("SEC") on or about October 28, 2009 to effect the voluntary delisting of its common stock from NASDAQ, if NTI's stockholders approve the dissolution of the company pursuant to a Plan of Complete Liquidation and Dissolution at the special meeting of stockholders planned for Tuesday, October 27, 2009.

Details of NTI's plans to pay an extraordinary dividend, delist its common stock from the Nasdaq Capital Market, discontinue recording transfers of stock, cease its reporting obligations under the Securities Exchange Act of 1934, as amended, and distribute its net cash to stockholders can be found in a definitive proxy statement filed with the SEC on September 22, 2009.

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions.

SOURCE Neurobiological Technologies, Inc.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
2. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center
3. Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
4. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
5. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
6. Neurobiological Technologies Announces Suspension of Viprinex Development
7. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
8. Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
9. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
10. Neurobiological Technologies Sets Date for First Quarter Financial Results
11. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  The Diabetes Research Institute (DRI), ... Miami Miller School of Medicine, announced today that ... test for the first time a novel transplant ... FDA approved Phase I/II study builds upon decades ... an important first step toward the development of ...
(Date:8/26/2015)... After litigating and negotiating patent infringement claims brought ... United States patent RE43,651 (the ,651 patent), ... United States without any admission or concession of ... a result of the parties, settlement, the US District Court ... dismissed the case without prejudice. Under the terms ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... lesions are cancerous is described by University of Illinois researchers in the ... and photonics. , In “ Breast cancer diagnosis using spatial light interference microscopy ...
(Date:8/25/2015)... PETERSBURG, Fla. , Aug. 25, 2015 /PRNewswire/ ... announced today that it has been awarded Certification ... Quality Assurance (NCQA). NCQA is ... quality. NCQA accredits and certifies a wide range of ... in key areas of performance. "Our ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4InformedDNA Achieves NCQA Utilization Management Certification 2
... Polytechnic Institute have developed a new method to harvest ... the creation of self-powered microsensors for more accurate and ... Koratkar, the researchers investigated how the flow of water ... small amounts of electricity. The research team demonstrated the ...
... , , • NT-KO-003, developed by ... neuroprotective effects that does not cause,immunosuppression. ... administered orally, whereas the few treatments available in,Spain require ... • NeuroAdvan, the Phase IIa clinical ...
... 2011 , Convergence Pharmaceuticals Limited ("Convergence"), ... value analgesic,medicines, today announces that the Phase II proof ... lumbosacral,radiculopathy (LSR) has started. LSR is a ... roots in the lumbar region of the spine. Common,features ...
Cached Biology Technology:New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 2New graphene discovery boosts oil exploration efforts, could enable self-powered microsensors 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 2Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 3Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 4Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects 5Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 2Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 3Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802 4
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is proud to announce that iMedNet ... technology platform, has led the way to significant and ... 2015.   Q2 2015 and Q1 2015 were, respectively, ... value sold in the company,s 15 year history.  In ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... team of scientists, led by Monash University researchers, has ... hospital patients worldwide - a discovery that has the ... of dollars each year. The research published today ... ways to genetically modify the bacterium Clostridium difficile ...
... with the 200th anniversary of the birth of Charles ... Behavioural Processes "Comparative Cognition in Context" was ... Hollis, the special issue features 16 papers original ... by leading researchers in the field of comparative cognition, ...
... issue of BioScience includes the following peer-reviewed articles: ... Science. , Patrick J. Tranel and David P. Horvath. ... including the development of herbicide-resistant crops and a better ... next generation of tools, including genomics, could yield novel ...
Cached Biology News:Monash scientists debug superbug 2BioScience tip sheet, March 2009 2
... Zero -mr agarose is ... no detectable endoosmosis, and is ... high molecular weight proteins or ... varying degrees of molecular sieving ...
... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... By incorporating a wide range of ... NX sets a new standard for flexible ... liquid handling including pipetting, dilution, dispensing, ... system thats as powerful and flexible as ...
Biology Products: